Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Denali Therapeutics (DNLI) Assets Average (2018 - 2025)

Historic Assets Average for Denali Therapeutics (DNLI) over the last 8 years, with Q3 2025 value amounting to $1.1 billion.

  • Denali Therapeutics' Assets Average fell 2485.02% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 2485.02%. This contributed to the annual value of $1.3 billion for FY2024, which is 329.21% down from last year.
  • According to the latest figures from Q3 2025, Denali Therapeutics' Assets Average is $1.1 billion, which was down 2485.02% from $1.2 billion recorded in Q2 2025.
  • Denali Therapeutics' Assets Average's 5-year high stood at $1.6 billion during Q1 2021, with a 5-year trough of $1.1 billion in Q3 2025.
  • Moreover, its 5-year median value for Assets Average was $1.4 billion (2022), whereas its average is $1.4 billion.
  • As far as peak fluctuations go, Denali Therapeutics' Assets Average soared by 15235.35% in 2021, and later tumbled by 2485.02% in 2025.
  • Denali Therapeutics' Assets Average (Quarter) stood at $1.4 billion in 2021, then fell by 5.83% to $1.3 billion in 2022, then fell by 11.06% to $1.2 billion in 2023, then rose by 18.3% to $1.4 billion in 2024, then dropped by 21.44% to $1.1 billion in 2025.
  • Its Assets Average stands at $1.1 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.3 billion for Q1 2025.